Meisoindigo targets PKMYT1 for degradation by acting as a molecular glue that enhances PKMYT1‐TRIM25 interaction, leading to K48‐linked ubiquitination and subsequent proteasomal degradation, thereby exerting therapeutic effects in chronic myeloid leukemia. Here, TRIM25 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.